Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and

Bihl, Florian K; Loggi, Elisabetta; Chisholm, John V; Hewitt, Hannah S; Henry, Leah M; Linde, Caitlyn; Suscovich, Todd J; Wong, Johnson T; Frahm, Nicole; Andreone, Pietro; Brander, Christian

doi:10.1186/1479-5876-3-20

Table 3 Optimal EBV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein	HLA Restriction	Sequence	Position	Reference
BMLF1	A1	LVSDYCNVLNKEFT	25–39	[27]
BMLF1	A2	GLCTLVAML	280–288	[28]
BMLF1	B18	DEVEFLGHY	397–405	[28]
BMLF1	n.d.*	KDTWLDARM	265–273	[29]
BMLF1	A24	DYNFVKQLF	320–328	[30]
BHRF	A2	LLWAARPRL	204–212	[31]
BZLF1	B7	LPCVLWPVL	44–52	[13]
BZLF1	B8	RAKFQLL	190–197	[32]
BZLF1	Cw6	RKCCRAKFKQLLQH	186–201	[1]
BMRF1	Cw6	YRSGIIAW	268–276	[16]
BMRF1	Cw3	FRNLAYGRTCVLGK	86–100	[16]
BRLF1	A2	YVLDHLIVV	109–117	[33]
BRLF1	A2	RALIKTLPRASYSSH	225–239	[27]
BRLF1	A3	RVRAYTYSK	148–156	[1]
BRLF1	A11	ATIGTAMYK	134–142	[16]
BRLF1	A24	DYCNVLNKEF	28–37	[27]
BRLF1	A24	TYPVLEEMF	198–206	[30]
BRLF1	B61	QKEEAAICGQMDLS	529–543	[1]
BRLF1	Cw4	ERPIFPHPSKPTFLP	393–407	[1]
gp110	A2	ILIYNGWYA	106–114	[1]
gp110	B35	VPGSETMCY	544–552	[1]
gp110	B35	APGWLIWTY	190–198	[1]
gp85	A2	TLFIGSHVV	420–428	[1]
gp85	A2	LMPIIPLINV	542–550	[1]
gp85	A2	SLVIVTTFV	225–233	[1]
gp350	A2	VLQWASLAV	863–871	[1]
gp350	A2	VLTLLLLLV	871–879	[34]
gp350	A2	LIPETVPYI	152–160	[34]
gp350	A2	QLTPHTKAV	67–75	[34]
EBNA1	A2	FMVFLQTHI	562–570	[13]
EBNA1	B7	RPQKRPSCI	72–80	[35]
EBNA1	B7	IPQCRLTPL	528–536	[35]
EBNA1	B53	HPVGEADYF	407–415	[35]
EBNA2	A2/B51	DTPLIPLTIF	42–50	[36]
EBNA3A	A2	SVRDRLARL	596–604	[37]
EBNA3A	A3	RLRAEAQVK	603–611	[38]
EBNA3A	A24	RYSIFFDY	246–253	[37]
EBNA3A	A29	VFSDGRVAC	491–499	[16]
EBNA3A	A30	AYSSWMYSY	176–184	[1]
EBNA3A	B7	RPPIFIRRL	379–387	[39]
EBNA3A	B7	VPAPAGPIV	502–510	[16]
EBNA3A	B8	QAKWRLQTL	158–166	[37]
EBNA3A	B8	FLRGRAYGL	325–333	[40]
EBNA3A	B35	YPLHEQYGM	458–466	[37]
EBNA3A	B46	VQPPQLTLQV	617–625	[41]
EBNA3A	B62	LEKARGSTY	406–414	[16]
EBNA3A	n.d.*	HLAAQGMAY	318–326	[16]
EBNA3B	A1l	NPTQAPVIQLHAVY	101–115	[40]
EBNA3B	A1l	AVFDRKSDAK	399–408	[16]
EBNA3B	A1l	LPGPQVTAVLLHEES	481–495	[40]
EBNA3B	A1l	DEPASTEPVHDQLL	551–563	[40]
EBNA3B	Al1	IVTDFSVIK	416–424	[40]
EBNA3B	A24	TYSAGIVQI	217–225	[16]
EBNA3B	A27	RRARSLSAERY	243–253	[42]
EBNA3B	B35	AVLLHEESM	488–496	[1]
EBNA3B	B44	VEITPYKPTW	657–666	[16]
EBNA3B	B58	VSFIEFVGW	279–287	[43]
EBNA3B	B62	GQGGSPTAM	831–839	[16]
EBNA3C	B7	QPRAPIRPI	881–889	[39]
EBNA3C	B27	RRIYDLIEL	258–266	[44]
EBNA3C	B27	HRCQAIRK	149–157	[16]
EBNA3C	B27	FRKAQIQGL	343–351	[16]
EBNA3C	B27	RKIYDLIEL	258–266	[45]
EBNA3C	B27	RRIFDLIEL	258–266	[45]
EBNA3C	B27	LRGKWQRRYR	249–258	[44]
EBNA3C	B37	LDFVRFMGV	285–293	[46]
EBNA3C	B39	HHIWQNLL	271–278	[16]
EBNA3C	B44	KEHVIQNAF	335–343	[47]
EBNA3C	B44	EENLLDFVRF	281–290	[40]
EBNA3C	B44	EGGVGWRHW	163–171	[48]
EBNA3C	B62	QNGALAINTF	213–222	[49]
EBNALP	A2	SLREWLLRI	284–292	[43]
LMP1	A2	YLQQNWWTL	159–167	[50]
LMP1	A2	YLLEMLWRL	125–133	[50]
LMP1	A2	LLVDLLWLL	167–175	[50]
LMP1	A2	TLLVDLLWL	166–174	[50]
LMP1	A2	LLLIALWNL	92–100	[50]
LMP1	B51	DPHGPVQLSYYD	393–404	[51]
LMP2	A2	FLYALALLL	356–364	[52]
LMP2	A2	LLWTLWLL	329–337	[53]
LMP2	A2	CLGGLLTMV	426–434	[54]
LMP2	A2	LTAGFLIFL	453–461	[53]
LMP2	A11	SSCSSCPLSKI	340–350	[53]
LMP2	A23	PYLFWLAAI	131–139	[55]
LMP2	A2	LLSAWILTA	447–455	[43]
LMP2	A24	TYGPVFMCL	419–427	[53]
LMP2	A24	IYVLVMLVL	222–230	[30]
LMP2	A25	VMNSNTLLSAW	442–451	[16]
LMP2	A27	RRRWRRLTV	236–244	[44]
LMP2	B40	IEDPPFNSL	200–208	[53]
LMP2	B63	WTLWLLI	331–338	[1]

*not determined

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com

Journal of Translational Medicine

Contact us